History
Hyperlipidemia refers to a state in which “fat (lipids) in the blood” is higher than normal, and it began as a term describing the test result (the numbers) itself. In the early days, evaluation was often done simply with total cholesterol alone, but over time it became established that there are many types of lipids, and that risk and treatment strategy differ depending on which lipid is high. In particular, from the mid-20th century onward, as several population studies repeatedly observed a tendency for cardiovascular events such as heart attack and stroke to occur more often the higher the cholesterol, “lipid management” became established as a core task of preventive medicine.
Another important change was the shift in perspective from “test values” to “lifetime risk.” Whereas the focus used to be on “whether it is within the normal range or not,” it later developed toward identifying “people at higher risk even with the same low-density lipoprotein cholesterol (LDL-C)” by also considering factors such as whether there is atherosclerotic cardiovascular disease (ASCVD), whether there is diabetes, whether the person smokes, and whether blood pressure is high. In this process, the indicators became subdivided into low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C).
The history of treatment has also changed greatly. The point that lifestyle modification is fundamental has been maintained, but as evidence accumulated that “lowering the numbers with medication actually reduces events,” drug therapy became established as standard treatment. Recent research emphasizes the view that reducing LDL-C exposure from a young age to lower the “cumulative exposure” can greatly lower long-term risk.
Causes
The causes of hyperlipidemia can be broadly divided into 1) inborn constitution (genetic factors) and 2) secondary factors caused by lifestyle, other diseases, and medications. The best-known genetic factor is familial hypercholesterolemia (FH), typically a case in which low-density lipoprotein cholesterol (LDL-C) remains very high from childhood. In such cases, it is common for the numbers not to fall sufficiently even with good dietary control, and a family history such as “someone in the family had a heart attack or stroke at a young age” is an important clue.
Secondary causes are much more common in clinical practice. A diet high in saturated and trans fats, frequent eating out, lack of physical activity, and weight gain can raise low-density lipoprotein cholesterol (LDL-C). In particular, sugary drinks and snacks and a diet centered on refined carbohydrates readily contribute to raising triglycerides (TG), and excessive drinking is also a common cause of elevated triglycerides (TG). In addition, coexisting conditions such as diabetes, hypothyroidism, nephrotic syndrome, and chronic kidney disease can shift lipid metabolism in an unfavorable direction and worsen the numbers. Medications can also be a cause, and some diuretics, beta-blockers, steroids, immunosuppressants, and others can raise low-density lipoprotein cholesterol (LDL-C) or triglycerides (TG) depending on the individual.
Recent research also emphasizes that lack of sleep, chronic stress, shift work, and irregular mealtimes can worsen body weight and insulin resistance, which can in turn lead to elevated triglycerides (TG) and reduced high-density lipoprotein cholesterol (HDL-C). In other words, if correction of the causes does not accompany treatment, management with medication alone can become unstable.
Genetic Epidemiology
Genetic epidemiology is the field that examines at the population level “how common certain genetic changes are, and what forms of hyperlipidemia and cardiovascular risk those changes actually tend to produce.” In some people, hyperlipidemia appears in the form of a “single-gene disorder” in which one gene variant has a large effect, but in many people the “multifactorial disease” form is more common, in which several genetic factors each add a little and environmental factors such as dietary habits, body weight, exercise, and sleep are layered on top. As a result, individual differences appear: with the same lifestyle, one person's low-density lipoprotein cholesterol (LDL-C) rises sharply while another person's triglycerides (TG) rise more.
The most representative single-gene disorder is familial hypercholesterolemia (FH). The genes commonly involved are the LDL receptor (LDLR), apolipoprotein B (APOB), PCSK9, and others, and a problem in the process of removing LDL from the blood causes LDL-C to remain high from childhood. Lipoprotein(a) (Lp(a)) is also frequently mentioned as an indicator with a strong genetic influence. Lp(a) is difficult to change substantially through lifestyle, and its inborn level can vary greatly from person to person, so it can provide additional information in “people whose low-density lipoprotein cholesterol (LDL-C) is similar but who develop cardiovascular disease unusually early or have a strong family history.”
Recent research emphasizes that in patients with suspected FH, genetic testing can serve not only as a diagnostic aid but also as the starting point for family screening (examination of family members), and that once a genetic risk is confirmed, the actual risk may be higher even with the same low-density lipoprotein cholesterol (LDL-C). However, because genetic information is a tool that indicates “probability,” not “destiny,” interpretation of the results is recommended to combine the numbers, family history, and coexisting risk factors.
General Epidemiology
General epidemiology deals with “how common hyperlipidemia is, in whom it appears more often, and in what living environments it increases.” Hyperlipidemia is a very common chronic health problem, and abnormalities of LDL-C tend to increase with age. As body weight increases and visceral fat accumulates, a pattern of rising TG and falling HDL-C becomes common, and high blood pressure and diabetes often accompany it at this point. This “state in which several risk factors appear bundled together” is also called metabolic syndrome.
In modern life, as time spent sitting at work increases and late-night eating, irregular meals, and consumption of high-calorie processed foods increase, lipid abnormalities are reported to be becoming more common. In particular, because TG elevation is strongly influenced by changes in body weight, alcohol, and sugar intake, the numbers can fluctuate greatly with even small changes in lifestyle. LDL-C, on the other hand, is subject to a relatively large genetic influence, so it is also common for it not to fall as much as expected with diet alone.
The biggest problem with hyperlipidemia is that “although there are usually no symptoms, it accumulates vascular damage over a long time.” Recent research emphasizes the view that “lifetime LDL-C exposure” from a young age can greatly determine the risk of cardiovascular disease after middle age, so the need for early detection and ongoing management is growing.
Pathogenesis
The core process by which hyperlipidemia raises the risk of cardiovascular disease is “fat building up inside the vessel wall, inflammation developing around it, and the vessel narrowing and hardening over time.” LDL-C plays the role of carrying cholesterol the body needs, but when the level is high and persists for a long time, some of it seeps into the inside of the vessel wall. In that process, when LDL is modified (by oxidation and so on), immune cells recognize it as a “danger signal” and gather to deal with it, and as the inflammatory response grows, a mass in which fat and immune cells have accumulated together (atherosclerotic plaque) is formed.
As the plaque grows, the vessel gradually narrows and blood flow decreases, and when the vessels supplying the heart narrow, “a feeling of chest tightness during exercise,” as in angina, can occur. A more dangerous situation is when the plaque surface is damaged and a thrombus (blood clot) forms rapidly. If this clot blocks a coronary artery, a heart attack can occur, and if it blocks a cerebral vessel, a cerebral infarction can occur, so treatment that lowers LDL-C is understood as “treatment that prevents vascular events.”
When TG is very high, the mechanism is partly different. When large fat particles increase in the blood, the blood becomes cloudy and the burden on the blood vessels and tissue of the pancreas increases, which can raise the risk of acute pancreatitis. Recent research proposes the view that not only TG itself but also the “lipid remnants” that carry TG can contribute to vascular risk.
Symptoms
Hyperlipidemia itself usually causes no symptoms. For this reason, many people first learn of it when they see their lipid test results at a health checkup. However, as atherosclerosis progresses over time, symptoms appear “in the form of complications” rather than being produced directly by hyperlipidemia. In other words, the appearance of symptoms means vascular damage may already have progressed to some degree, so management at the stage before symptoms develop is more important. When the blood vessels of the heart narrow, symptoms such as chest pain or pressure, shortness of breath during exercise, or tiring easily can occur.
When cerebral blood vessels become blocked or narrowed, neurological symptoms can appear, such as weakness or reduced sensation in an arm and leg on one side, slurred speech, or sudden blurring of vision on one side. When peripheral artery disease develops with narrowing of the blood vessels of the legs, “intermittent claudication” can appear, in which calf pain develops while walking and improves with rest. When TG is very high and acute pancreatitis occurs, acute abdominal symptoms such as upper abdominal pain, nausea and vomiting, and fever can appear, and this can be an emergency.
However, because in most people hyperlipidemia is “a state with no sensation in which risk accumulates,” treatment decisions should be based on the level of risk (age, family history, diabetes, blood pressure, smoking, chronic kidney disease, etc.) rather than on the presence or absence of symptoms. Recent research continues to discuss that lowering LDL-C earlier and more intensively in people at high risk may be advantageous for reducing long-term events.
Signs
Signs visible on physical examination or in appearance are not common, but when found, they help in inferring the cause (especially genetic forms). Typically, xanthoma and xanthelasma are lesions that appear yellow because fat is deposited in the skin, tendons, or around the eyelids. Tendon xanthomas that form in tendons such as the Achilles tendon can be a clue that raises suspicion of familial hypercholesterolemia (FH). Corneal arcus is a change in which a grayish-white ring is seen at the edge of the cornea, and if it is prominent at a young age, an association with lipid abnormalities can be considered.
However, hyperlipidemia can well be present even without these findings, and in fact it mostly progresses without any change in appearance. Therefore, in practice, the most important sign is an abnormality on blood tests. Elevated LDL-C, elevated TG, low HDL-C, or a mixed type is identified. In addition, hyperlipidemia often appears together with obesity, fatty liver, high blood pressure, and diabetes, so if there are metabolic risk signals such as an increased waist circumference or elevated blood pressure, it is advisable to check lipid tests more proactively.
Also, in some people it is difficult to explain the risk fully with LDL-C alone, so indicators such as apolipoprotein B (ApoB) or non-HDL-C can provide additional information. ApoB is explained as a concept related to “the number of lipid particles that can enter the blood vessels,” and there is discussion that it may better reflect risk when TG is high or there is a mixed-type abnormality.
Screening
Screening is a method for finding hyperlipidemia in advance in people without symptoms. The most basic is a lipid test (lipid panel) done by blood test, which measures total cholesterol (TC), LDL-C, HDL-C, and TG. In the past, fasting blood draws were the standard, but now nonfasting tests are also widely used in many situations. However, when an accurate evaluation is needed because TG came out high, or when very high TG is suspected, a fasting test may be more accurate.
“When, for whom, and how often” to screen differs depending on the national health checkup system and guidelines, but in adults it is common to repeat lipid tests at regular intervals and to check more often the more risk factors there are. If someone in the family had a heart attack or stroke at a young age, or if you yourself have risk factors such as obesity, high blood pressure, diabetes, or smoking, testing can be considered at an even earlier age.
In particular, when familial hypercholesterolemia (FH) is suspected, “family screening (cascade screening)” is very important. When one person is diagnosed, it is highly likely that others in the family have the same constitution, and early detection at the family level can greatly change the long-term prognosis. Recent research discusses that for items with a large genetic influence, such as Lp(a), measuring once can serve as a reference for lifetime risk assessment.
Diagnosis
Diagnosis can be understood as a process of 1) checking lipid levels to classify the type, 2) looking for secondary causes, and 3) assessing the individual's cardiovascular risk to determine treatment intensity. First, LDL-C, HDL-C, TG, and TC are checked on a lipid test to determine which item is mainly the problem (e.g., LDL-C-predominant, TG-predominant, or mixed type). Next, the presence of secondary causes such as hypothyroidism, diabetes, kidney disease, liver disease, medications being taken, and drinking habits is checked. If familial hypercholesterolemia (FH) is suspected, clinical diagnostic criteria are applied by combining findings such as the height of LDL-C, family history, and xanthomas.
In addition, atherosclerotic cardiovascular disease (ASCVD) risk is assessed to determine the need for treatment and set goals. This includes age, sex, blood pressure, smoking, diabetes, cholesterol levels, and so on, and in some cases imaging indicators such as the coronary artery calcium score (CAC score) help with decisions in “people whose risk is uncertain.” After treatment, follow-up testing is important. It is necessary to check together whether the target level has been reached, whether there are medication side effects (muscle pain, elevated liver enzymes, etc.), whether lifestyle changes are being maintained, and whether medication is being taken consistently (adherence).
Recent research points out that “doing well at first and then having treatment interrupted partway” is one of the important causes of poor long-term prognosis, emphasizing that consistency is as important as diagnosis.
Treatment
The broad goal of treatment is “to lower lipid levels and thereby reduce events such as heart attack and stroke that can occur over time.” The most basic step is lifestyle modification. A diet that reduces saturated and trans fats and increases vegetables, whole grains, legumes, nuts, and fish is helpful. It is advisable to cut down on sweets, processed foods, and excessive drinking, and losing weight often lowers TG and improves HDL-C. For exercise, combining aerobic exercise and strength training is a realistic approach, and quitting smoking greatly helps reduce vascular damage itself.
Drug therapy is determined according to the individual's level of risk and LDL-C level. The basic drug is a statin, which lowers LDL-C by reducing cholesterol synthesis in the liver and increasing the capacity to remove LDL. If the target is not reached, it is common to add ezetimibe, which inhibits cholesterol absorption in the intestine. In very high-risk groups, when LDL-C is not lowered sufficiently even with a statin and ezetimibe, or when the underlying risk is high as in familial hypercholesterolemia (FH), treatment with the PCSK9 inhibitor class can be considered.
When TG is high, the goal is somewhat different. When TG is “very high” and there is a risk of pancreatitis, lowering TG in the short term is the priority, and reducing alcohol and sugar is most effective. Recent research reports that certain omega-3 preparations may help reduce cardiovascular risk, but it is emphasized that results can differ depending on the type and dose of preparation, so the choice should be made according to the purpose.
Prognosis
Prognosis is determined not only by “how high the lipid levels were,” but also by “how long they persisted (cumulative exposure),” “how many other risk factors there are,” and “how consistently treatment is maintained.” When LDL-C remains high for a long time, plaque gradually builds up in the vessel walls, increasing the risk of heart attack, stroke, and peripheral artery disease. Conversely, in people at high risk, lowering LDL-C sufficiently and maintaining this over the long term can meaningfully reduce the risk of events. When there is a clear genetic cause, as in familial hypercholesterolemia (FH), early diagnosis greatly changes the prognosis.
When TG is very high, the key to prognosis is preventing acute pancreatitis. Because the risk of hospitalization and complications can increase the more often pancreatitis recurs, it is important to lower TG stably through limiting alcohol and sugar, weight management, and drug therapy when necessary. Recent research shows that new targeted therapies to lower TG are being developed, and the possibility of broader treatment options, especially for certain genetic causes (such as chylomicronemia), is being discussed.
Finally, what realistically determines prognosis is sustainability. The judgment that “the numbers have improved, so it is fine to stop the medication” can be dangerous, and if the numbers rise again after treatment is stopped, the risk can accumulate again. Recent research emphasizes maintaining long-term treatment as one of the keys to reducing events, and says that an approach that also takes into account side effect management and the convenience of taking medication is important.
Prevention
Prevention is easier to understand when divided into primary prevention (preventing occurrence when there is not yet cardiovascular disease) and secondary prevention (preventing recurrence in people who already have cardiovascular disease). The core of primary prevention is lifestyle. Reducing saturated and trans fats, increasing vegetables, whole grains, fish, legumes, and nuts, and cutting down on sugary foods and heavy drinking are helpful. Regular exercise, weight management, and quitting smoking have a positive effect not only on lipid levels but also on blood pressure, blood sugar, and inflammatory status, lowering overall risk.
Another very important aspect of prevention is “not putting off testing.” Because hyperlipidemia is asymptomatic in most cases, it cannot be known without testing. In secondary prevention, drug therapy takes on a larger role. People who have already had a heart attack, angina, stroke, or peripheral artery disease have a high risk of recurrence, so the LDL-C target often becomes stricter. It is important to consistently maintain statin-based treatment and, if necessary, add ezetimibe or PCSK9-class treatment to reach the target.
Prevention is ultimately closer to “lifelong management.” Lifestyle changes succeed when they are designed in a way that is sustainable for the individual, rather than changed like a short-lived fad. Adjusting medications in consultation with the medical team rather than stopping them on your own, and receiving regular follow-up tests, is the most realistic and proven way to reduce complications.